{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:47:27Z","timestamp":1785901647486,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Arhalofenate is a novel antiinflammatory uricosuric agent. The objective of this study was to evaluate its antiflare activity in patients with gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a 12\u2010week, randomized, double\u2010blind, controlled phase IIb study. Eligible patients had had \u22653 flares of gout during the previous year, had discontinued urate\u2010lowering therapy and colchicine, and had a serum uric acid (UA) level of 7.5\u201312 mg\/dl. Patients were randomly assigned at a 2:2:2:2:1 ratio to receive 600 mg arhalofenate, 800 mg arhalofenate, 300 mg allopurinol, 300 mg allopurinol plus 0.6 mg colchicine, or placebo once a day. The primary outcome measure was the flare incidence (number of flares divided by time of exposure). The serum UA level was a secondary outcome measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 239 gout patients were randomized and took at least 1 dose of study medication. The primary outcome measure comparing flare incidence between 800 mg arhalofenate and 300 mg allopurinol was achieved, with a 46% decrease in the 800 mg arhalofenate group (0.66 versus 1.24;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0056). Treatment with 800 mg arhalofenate was also significantly better than placebo (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.049) and not significantly different from treatment with 300 mg allopurinol plus 0.6 mg colchicine (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.091). Mean changes in serum UA level were \u221212.5% with 600 mg arhalofenate and \u221216.5% with 800 mg arhalofenate (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001, respectively, versus \u22120.9% with placebo). There were no meaningful differences in adverse events (AEs) between groups, and there were no serious AEs related to arhalofenate. Urinary calculus occurred in 1 patient receiving 300 mg allopurinol. No abnormal serum creatinine values &gt;1.5\u2010fold the baseline value were observed in the arhalofenate\u2010treated groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Arhalofenate at a dosage of 800 mg decreased gout flares significantly compared to allopurinol at a dosage of 300 mg. Arhalofenate was well tolerated and appeared safe. Arhalofenate is the first urate\u2010lowering antiflare therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.39684","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T03:25:23Z","timestamp":1458357923000},"page":"2027-2034","source":"Crossref","is-referenced-by-count":78,"title":["A Randomized, Double\u2010Blind, Active\u2010 and Placebo\u2010Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout"],"prefix":"10.1002","volume":"68","author":[{"given":"Jeffrey","family":"Poiley","sequence":"first","affiliation":[{"name":"Arthritis Associates Orlando Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"CymaBay Therapeutics Newark California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun\u2010Jung","family":"Choi","sequence":"additional","affiliation":[{"name":"CymaBay Therapeutics Newark California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Davis","sequence":"additional","affiliation":[{"name":"CSD Biostatistics Tucson Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Martin","sequence":"additional","affiliation":[{"name":"CymaBay Therapeutics Newark California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"McWherter","sequence":"additional","affiliation":[{"name":"CymaBay Therapeutics Newark California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol F.","family":"Boudes","sequence":"additional","affiliation":[{"name":"CymaBay Therapeutics Newark California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Arhalofenate Flare Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2013.04.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.540874"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.533647"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000031"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204647"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_2_8_11_1","volume-title":"Colcrys [package insert]","year":"2012"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.09.012"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.2860"},{"key":"e_1_2_8_14_1","first-page":"S697","article-title":"Arhalofenate is a novel dual\u2010acting agent with uricosuric and anti\u2010inflammatory properties [abstract]","volume":"64","author":"Choi YJ","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.1814"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20549"},{"key":"e_1_2_8_18_1","first-page":"367","volume-title":"Categorical data analysis using SAS","author":"Stokes ME","year":"2012"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33483"},{"key":"e_1_2_8_20_1","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3531"},{"issue":"10","key":"e_1_2_8_22_1","article-title":"A study to evaluate the pharmacodynamics, pharmacokinetics and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout [abstract]","volume":"67","author":"Steinberg A","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_23_1","first-page":"104","article-title":"Frequency and predictors of inappropriate management of recurrent gout attack in a longitudinal study","volume":"33","author":"Neogi T","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3273"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.39684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T18:06:08Z","timestamp":1759946768000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1002\/art.39684"],"URL":"https:\/\/doi.org\/10.1002\/art.39684","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726225272.793528705","asserted-by":"object"}]},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}